bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2017: O S A J J M A M F J
2016: D N O

 
  Other news for:
Brain Neoplasms
Cervix Neoplasms
Colonic Neoplasms
Lung Neoplasms
 Resources from HONselect
FDA OKs First 'Biosimilar' Drug to Fight Cancer
New biologic could help drive down the cost of care, agency says

By Robert Preidt

THURSDAY, Sept. 14, 2017 (HealthDay News) -- The first approval of a biosimilar drug to treat cancer was announced Thursday by the U.S. Food and Drug Administration.

Mvasi (bevacizumab-awwb) was approved as a biosimilar to Avastin (bevacizumab) for the treatment of adults with certain colon, lung, brain, kidney and cervical cancers.

A biosimilar is a biological product that is approved because it is highly similar to an already-approved biologic drug and has no significant differences in safety and effectiveness from the first product, the FDA explained.

"Bringing new biosimilars to patients, especially for diseases where the cost of existing treatments can be high, is an important way to help spur competition that can lower health care costs and increase access to important therapies," FDA Commissioner Dr. Scott Gottlieb said in an agency news release.

Mvasi is marketed by Amgen, Inc., headquartered in Thousand Oaks, Calif.

Like Avastin, the labeling for Mvasi has a boxed warning about an increased risk of: holes in the stomach and intestines; surgery and wound healing complications; and severe or fatal pulmonary, gastrointestinal, central nervous system and vaginal bleeding.

Common side effects of Mvasi include nosebleeds, headache, high blood pressure, inflammation of the nasal cavity, high levels of protein in the urine, taste alteration, dry skin, rectal bleeding, excessive tear production, back pain and skin irritation, according to the FDA.

Women who are pregnant should not take Mvasi because it may cause harm to a developing fetus.

More information

The U.S. Food and Drug Administration has more on biosimilars.

SOURCE: U.S. Food and Drug Administration, news release, Sept. 14, 2017

Copyright © 2017 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=726546

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Neoplasms
Brain
Therapeutics
Lung
Hemorrhage
Back Pain
Wounds and Injuries
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact